Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016991302> ?p ?o ?g. }
- W2016991302 endingPage "2771" @default.
- W2016991302 startingPage "2764" @default.
- W2016991302 abstract "West African studies have hypothesized that increased female mortality after high-titre measles vaccine (HTMV) was due to subsequent diphtheria–tetanus–pertussis (DTP) and inactivated polio vaccine (IPV) vaccinations. We tested two deductions from this hypothesis in HTMV studies from rural Sudan and Kinshasa; first, there should be no excess female mortality for HTMV recipients when DTP was not given after HTMV and second, excess female mortality should only be found among those children who received DTP after HTMV. The Sudanese trial randomised 510 children to Edmonston–Zagreb (EZ) HTMV, Connaught HTMV or a control vaccine (meningococcal). Both the Connaught HTMV and the control group received standard measles vaccine at 9 months. In the Kinshasa study 1023 children received one dose of HTMV at 6 months or two doses at 312 and 912 months of age. First, the Sudan trial is one of the few randomised studies of measles vaccine; the EZ HTMV group had lower mortality between 5 and 9 months of age than controls, the mortality ratio (MR) being 0.00 (p = 0.030). This effect was not due to prevention of measles infection. Second, both studies provided evidence that HTMV per se was associated with low mortality. In a combined analysis comparing both HTMV groups with controls, the HTMV groups had a MR of 0.09 (0.01–0.71) between 5 and 9 months of age. In Kinshasa, the HTMV recipients who did not receive simultaneous DTP had an annual mortality rate of only 1.0% between 6 months and 3 years of age. Third, the female–male MR was related to subsequent DTP vaccinations. In Kinshasa, the female–male MR was only 0.40 (0.13–1.27) among the HTMV recipients who did not receive further doses of DTP. In Sudan, the female–male mortality ratio in the EZ group was 3.89 (95% CI 1.02–14.83) and the female–male MR increased with number of doses of DTP likely to have been given during follow-up (trend, p = 0.043). Fourth, in Kinshasa, mortality was higher among children who had received HTMV and DTP simultaneously than among children who had received HTMV alone (MR = 5.38 (1.37–21.2)). Measles vaccine is associated with non-specific beneficial effects. When not given with DTP, HTMV per se was associated with low mortality. Increased female mortality was not found among children who did not receive DTP after HTMV. Hence, our deductions were supported and the sequence or combination of vaccinations may have an effect on sex-specific mortality patterns in low-income countries." @default.
- W2016991302 created "2016-06-24" @default.
- W2016991302 creator A5017577494 @default.
- W2016991302 creator A5028407518 @default.
- W2016991302 creator A5037482092 @default.
- W2016991302 creator A5077376427 @default.
- W2016991302 date "2006-04-01" @default.
- W2016991302 modified "2023-10-17" @default.
- W2016991302 title "The sequence of vaccinations and increased female mortality after high-titre measles vaccine: Trials from rural Sudan and Kinshasa" @default.
- W2016991302 cites W1584448102 @default.
- W2016991302 cites W1587247212 @default.
- W2016991302 cites W1827995782 @default.
- W2016991302 cites W1993670292 @default.
- W2016991302 cites W1994917397 @default.
- W2016991302 cites W2001361637 @default.
- W2016991302 cites W2003619575 @default.
- W2016991302 cites W2008675520 @default.
- W2016991302 cites W2009058395 @default.
- W2016991302 cites W2009203266 @default.
- W2016991302 cites W2014480218 @default.
- W2016991302 cites W2023812091 @default.
- W2016991302 cites W2060349094 @default.
- W2016991302 cites W2069760010 @default.
- W2016991302 cites W2071974172 @default.
- W2016991302 cites W2101538150 @default.
- W2016991302 cites W2113342438 @default.
- W2016991302 cites W2129764321 @default.
- W2016991302 cites W2135115112 @default.
- W2016991302 cites W2136320887 @default.
- W2016991302 cites W2159805006 @default.
- W2016991302 cites W2260825330 @default.
- W2016991302 doi "https://doi.org/10.1016/j.vaccine.2006.01.004" @default.
- W2016991302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16457909" @default.
- W2016991302 hasPublicationYear "2006" @default.
- W2016991302 type Work @default.
- W2016991302 sameAs 2016991302 @default.
- W2016991302 citedByCount "51" @default.
- W2016991302 countsByYear W20169913022012 @default.
- W2016991302 countsByYear W20169913022013 @default.
- W2016991302 countsByYear W20169913022014 @default.
- W2016991302 countsByYear W20169913022015 @default.
- W2016991302 countsByYear W20169913022016 @default.
- W2016991302 countsByYear W20169913022017 @default.
- W2016991302 countsByYear W20169913022018 @default.
- W2016991302 countsByYear W20169913022019 @default.
- W2016991302 countsByYear W20169913022020 @default.
- W2016991302 countsByYear W20169913022021 @default.
- W2016991302 countsByYear W20169913022023 @default.
- W2016991302 crossrefType "journal-article" @default.
- W2016991302 hasAuthorship W2016991302A5017577494 @default.
- W2016991302 hasAuthorship W2016991302A5028407518 @default.
- W2016991302 hasAuthorship W2016991302A5037482092 @default.
- W2016991302 hasAuthorship W2016991302A5077376427 @default.
- W2016991302 hasConcept C126322002 @default.
- W2016991302 hasConcept C159654299 @default.
- W2016991302 hasConcept C179755657 @default.
- W2016991302 hasConcept C187212893 @default.
- W2016991302 hasConcept C203014093 @default.
- W2016991302 hasConcept C22070199 @default.
- W2016991302 hasConcept C2776438120 @default.
- W2016991302 hasConcept C2779841045 @default.
- W2016991302 hasConcept C2780572238 @default.
- W2016991302 hasConcept C2780657872 @default.
- W2016991302 hasConcept C2780801004 @default.
- W2016991302 hasConcept C2908647359 @default.
- W2016991302 hasConcept C4870876 @default.
- W2016991302 hasConcept C71924100 @default.
- W2016991302 hasConcept C99454951 @default.
- W2016991302 hasConceptScore W2016991302C126322002 @default.
- W2016991302 hasConceptScore W2016991302C159654299 @default.
- W2016991302 hasConceptScore W2016991302C179755657 @default.
- W2016991302 hasConceptScore W2016991302C187212893 @default.
- W2016991302 hasConceptScore W2016991302C203014093 @default.
- W2016991302 hasConceptScore W2016991302C22070199 @default.
- W2016991302 hasConceptScore W2016991302C2776438120 @default.
- W2016991302 hasConceptScore W2016991302C2779841045 @default.
- W2016991302 hasConceptScore W2016991302C2780572238 @default.
- W2016991302 hasConceptScore W2016991302C2780657872 @default.
- W2016991302 hasConceptScore W2016991302C2780801004 @default.
- W2016991302 hasConceptScore W2016991302C2908647359 @default.
- W2016991302 hasConceptScore W2016991302C4870876 @default.
- W2016991302 hasConceptScore W2016991302C71924100 @default.
- W2016991302 hasConceptScore W2016991302C99454951 @default.
- W2016991302 hasFunder F4320325957 @default.
- W2016991302 hasIssue "15" @default.
- W2016991302 hasLocation W20169913021 @default.
- W2016991302 hasLocation W20169913022 @default.
- W2016991302 hasOpenAccess W2016991302 @default.
- W2016991302 hasPrimaryLocation W20169913021 @default.
- W2016991302 hasRelatedWork W1488089181 @default.
- W2016991302 hasRelatedWork W2021440477 @default.
- W2016991302 hasRelatedWork W2042066151 @default.
- W2016991302 hasRelatedWork W2082556352 @default.
- W2016991302 hasRelatedWork W2278141396 @default.
- W2016991302 hasRelatedWork W2334015808 @default.
- W2016991302 hasRelatedWork W2362614420 @default.
- W2016991302 hasRelatedWork W2416883071 @default.
- W2016991302 hasRelatedWork W324855215 @default.